Cancer Epidemiology Biomarkers & Prevention · 2013 · 173 citations · 31 references
Life SciencesBiostatisticsEpidemiologic MethodsMass Spectrometric AnalysisMetabolomicsCancer MetabolomicsMass Spectrometry-based MetabolomicsMetabolic VariabilityMetabolism VariabilityMetabolite ProfilingMetabolite QuantificationDisease Metabolite ProfilingGas Chromatography-mass SpectrometryLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisMetabolomic BiomarkersOvarian Cancer ScreeningRelative Risk EstimationWithin-patient Variability
BACKGROUND: Metabolite levels within an individual vary over time. This within-individual variability, coupled with technical variability, reduces the power for epidemiologic studies to detect associations with disease. Here, the authors assess the variability of a large subset of metabolites and evaluate the implications for epidemiologic studies. METHODS: Using liquid chromatography/mass spectrometry (LC/MS) and gas chromatography-mass spectroscopy (GC/MS) platforms, 385 metabolites were measured in 60 women at baseline and year-one of the Shanghai Physical Activity Study, and observed patterns were confirmed in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening study. RESULTS: Although the authors found high technical reliability (median intraclass correlation = 0.8), reliability over time within an individual was low. Taken together, variability in the assay and variability within the individual accounted for the majority of variability for 64% of metabolites. Given this, a metabolite would need, on average, a relative risk of 3 (comparing upper and lower quartiles of "usual" levels) or 2 (comparing quartiles of observed levels) to be detected in 38%, 74%, and 97% of studies including 500, 1,000, and 5,000 individuals. Age, gender, and fasting status factors, which are often of less interest in epidemiologic studies, were associated with 30%, 67%, and 34% of metabolites, respectively, but the associations were weak and explained only a small proportion of the total metabolite variability. CONCLUSION: Metabolomics will require large, but feasible, sample sizes to detect the moderate effect sizes typical for epidemiologic studies. IMPACT: We offer guidelines for determining the sample sizes needed to conduct metabolomic studies in epidemiology.
31
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Zeneng Wang, Elizabeth Klipfell, Brian J. Bennett et al. · Nature · 2011 · 5.6K citations
HMDB: the Human Metabolome Database
David S. Wishart, Dorit Tzur, Craig Knox et al. · Nucleic Acids Research · 2007 · 3.3K citations · Full text
Metabolite profiles and the risk of developing diabetes
Thomas J. Wang, Martin G. Larson, Ramachandran S. Vasan et al. · Nature Medicine · 2011 · 3.1K citations · Full text
Orthogonal projections to latent structures (O‐PLS)
Johan Trygg, Svante Wold · Journal of Chemometrics · 2002 · 2.4K citations
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar, Laila Poisson, Thekkelnaycke M. Rajendiran et al. · Nature · 2009 · 2.2K citations · Full text
Medicine, Cancer Biology, Oncology +16